| Name | Company | P/L % | MPV |
|
|---|---|---|---|---|
| Lord Glendonbrook |
|
Stryker / NYQ:SYK | 293.20% | £275,240.56 |
| Lord Glendonbrook |
|
Abbott Laboratories / NYQ:ABT | 282.68% | £267,878.90 |
| Lord Sassoon |
|
Abbott Laboratories / NYQ:ABT | 193.89% | £205,723.40 |
| Lord Grabiner |
|
Boston Scientific / NYQ:BSX | 138.22% | £166,757.37** |
| Baroness Noakes |
|
Smith & Nephew / NYQ:SNN | 26.69% | £88,682.80 |
| Lord Glendonbrook |
|
Smith & Nephew / NYQ:SNN | 17.58% | £82,309.07 |
| Lord Glendonbrook |
|
Medtronic / NYQ:MDT | 10.66% | £77,463.33** |
| Lord Mance |
|
Stryker / NYQ:SYK | -0.74% | £69,480.73 |
| Lord Howard of Rising |
|
Ekf Diagnostics / LSE:EKF.L | -1.24% | £69,131.79 |
| Baroness Deech |
|
Smith & Nephew / NYQ:SNN | -10.92% | £62,352.55 |
| Lord Londesborough |
|
Abbott Laboratories / NYQ:ABT | -11.15% | £62,197.21 |
| Lord Sassoon |
|
Medtronic / NYQ:MDT | -14.22% | £60,045.65 |
| Lord Glendonbrook |
|
Align Technology / NMS:ALGN | -46.90% | £37,167.12 |
| Lord Kakkar | Cyte / NMS:CTKB | -55.35% | £31,251.50** | |
| Lord Browne of Madingley | Allurion / NYQ:ALUR | -76.53% | £16,432.02 |